Kura Oncology (KURA) Operating Leases (2020 - 2026)

Kura Oncology (KURA) has 7 years of Operating Leases data on file, last reported at $13.2 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $13.2 million, up 68.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.2 million (up 68.08% YoY), and the FY2025 annual result was $9.5 million, up 82.45% from the prior year.
• Operating Leases climbed to $13.2 million in Q1 2026 per KURA's latest filing, from $9.5 million in the prior quarter.
• Over five years, Operating Leases peaked at $13.2 million in Q1 2026 and troughed at $1.5 million in Q2 2023.
• A 5-year average of $5.9 million and a median of $5.8 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases plunged 59.61% in 2023, then jumped 301.58% in 2024.
• A 5-year view of Operating Leases shows it stood at $2.5 million in 2022, then surged by 149.69% to $6.4 million in 2023, then dropped by 18.42% to $5.2 million in 2024, then jumped by 82.45% to $9.5 million in 2025, then soared by 39.84% to $13.2 million in 2026.
• Business Quant data shows KURA's Operating Leases at $13.2 million in Q1 2026, $9.5 million in Q4 2025, and $8.4 million in Q3 2025.